Biotechnology (61) | Retention Agreements (61)
Browse by Company
-
AbbVie Inc. (3)
-
AKCEA THERAPEUTICS, INC. (1)
-
Akebia Therapeutics, Inc. (2)
-
Alector, Inc. (1)
-
Anika Therapeutics (3)
-
Apellis Pharmaceuticals, Inc. (1)
-
AQUINOX PHARMACEUTICALS, INC (1)
-
ARDELYX, INC. (5)
-
ATHERSYS, INC (4)
-
Chelsea Worldwide Inc. (1)
-
EXICURE, INC. (1)
-
FIVE PRIME THERAPEUTICS INC (3)
-
FS Development Corp. (1)
-
Gilead Sciences (1)
-
Karyopharm Therapeutics Inc. (1)
-
Minerva Neurosciences, Inc. (10)
-
Moderna, Inc. (3)
-
Momenta Pharmaceuticals, Inc. (3)
-
Myriad Genetics, Inc. (1)
-
PDL BIOPHARMA, INC. (1)
-
Praxis Precision Medicines, Inc. (1)
-
Relay Therapeutics, Inc. (2)
-
RenovaCare, Inc. (1)
-
Sesen Bio, Inc. (2)
-
Spring Bank Pharmaceuticals, Inc. (1)
-
SpringWorks Therapeutics, Inc. (2)
-
SUNESIS PHARMACEUTICALS INC (1)
-
Translate Bio, Inc. (2)
-
TYME TECHNOLOGIES, INC. (1)
-
XOMA Corp (1)
Recent Contracts
-
Form of Officer Retention Letter Agreement
(Akebia Therapeutics, Inc., Filed With SEC on May 9, 2022)
-
Form of Retention and Separation Agreement for Michel Dahan and Nicole R. Hadas
(Akebia Therapeutics, Inc., Filed With SEC on May 9, 2022)
-
Form of AbbVie Inc. Retention RSU Agreement Ratable Vesting
(AbbVie Inc., Filed With SEC on May 6, 2022)
-
Form of AbbVie Inc. Retention RSU Agreement Cliff Vesting with Dividend Equivalent Accrual
(AbbVie Inc., Filed With SEC on May 6, 2022)
-
Retention Agreement, dated
(SpringWorks Therapeutics, Inc., Filed With SEC on May 5, 2022)
-
Retention Agreement, dated May 2, 2022, by and between SpringWorks Therapeutics, Inc. and L. Mary Smith
(SpringWorks Therapeutics, Inc., Filed With SEC on May 5, 2022)
-
The Retention and Severance Plan dated, March 31, 2022
(XOMA Corp, Filed With SEC on May 5, 2022)
-
Form of Retention Agreement by and between Tyme Technologies, Inc. and certain of its individual officers
(TYME TECHNOLOGIES, INC., Filed With SEC on April 29, 2022)
-
Retention Agreement by and between Exicure, Inc. and Elias D. Papadimas
(EXICURE, INC., Filed With SEC on March 25, 2022)
-
Executive Retention Agreement, dated August 10, 2020, by and between Anika Therapeutics, Inc. and Michael Levitz
(Anika Therapeutics, Filed With SEC on March 11, 2022)
